FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000309674> ?p ?o ?g. }

• W2000309674 endingPage "308" @default.
• W2000309674 startingPage "299" @default.
• W2000309674 abstract "BACKGROUND Sleep-disordered breathing may impair cerebral oxygenation in patients with OSA syndrome, in particular during altitude travel. We studied cerebral tissue oxygenation (CTO) at low and moderate altitude in patients with OSA and evaluated whether acetazolamide improved CTO. METHODS Eighteen patients with OSA living at < 600 m discontinued CPAP therapy during studies in Zurich (490 m) and during two sojourns of 3 days in the Swiss Alps (2 days at 1,860 m and 1 day at 2,590 m) separated by a 2-week washout period at < 600 m. Patients received acetazolamide (2 × 250 mg/d) or placebo at altitude in a randomized, double-blind, crossover design. Nocturnal polysomnography, including CTO monitoring by near-infrared spectroscopy (NIRS), was performed. RESULTS At 490 m, medians of CTO, peripheral oxygen saturation as measured by pulse oximetry (Spo2), and apnea/hypopnea index were 65%, 93%, and 57.3/h, respectively. At 2,590 m, on placebo, the corresponding values were 59%, 86%, and 86.4/h, respectively (P < .05, all corresponding comparisons). Acetazolamide increased CTO and Spo2 at 2,590 m by mean values of 2% (95% CI, 0%-4%) and 2% (95% CI, 1%-3%), respectively, and reduced the apnea/hypopnea index by 23.4/h (95% CI, 14.0-32.8/h) (P < .05, all changes). Cerebral total hemoglobin concentration, a NIRS-derived surrogate reflecting regional cerebral blood volume, increased by a similar degree in response to apneas at 490 m and 2,590 m and during acetazolamide and placebo treatment. CONCLUSIONS In patients with OSA staying at altitude, nocturnal cerebral and arterial oxygenation were reduced in association with exacerbated sleep apnea. Acetazolamide partially improved CTO, Spo2, and sleep apnea without impairing the cerebral blood flow response to apneas. TRIAL REGISTRY ClinicalTrials.gov; No.: NCT00714740; URL: www.clinicaltrials.gov Sleep-disordered breathing may impair cerebral oxygenation in patients with OSA syndrome, in particular during altitude travel. We studied cerebral tissue oxygenation (CTO) at low and moderate altitude in patients with OSA and evaluated whether acetazolamide improved CTO. Eighteen patients with OSA living at < 600 m discontinued CPAP therapy during studies in Zurich (490 m) and during two sojourns of 3 days in the Swiss Alps (2 days at 1,860 m and 1 day at 2,590 m) separated by a 2-week washout period at < 600 m. Patients received acetazolamide (2 × 250 mg/d) or placebo at altitude in a randomized, double-blind, crossover design. Nocturnal polysomnography, including CTO monitoring by near-infrared spectroscopy (NIRS), was performed. At 490 m, medians of CTO, peripheral oxygen saturation as measured by pulse oximetry (Spo2), and apnea/hypopnea index were 65%, 93%, and 57.3/h, respectively. At 2,590 m, on placebo, the corresponding values were 59%, 86%, and 86.4/h, respectively (P < .05, all corresponding comparisons). Acetazolamide increased CTO and Spo2 at 2,590 m by mean values of 2% (95% CI, 0%-4%) and 2% (95% CI, 1%-3%), respectively, and reduced the apnea/hypopnea index by 23.4/h (95% CI, 14.0-32.8/h) (P < .05, all changes). Cerebral total hemoglobin concentration, a NIRS-derived surrogate reflecting regional cerebral blood volume, increased by a similar degree in response to apneas at 490 m and 2,590 m and during acetazolamide and placebo treatment. In patients with OSA staying at altitude, nocturnal cerebral and arterial oxygenation were reduced in association with exacerbated sleep apnea. Acetazolamide partially improved CTO, Spo2, and sleep apnea without impairing the cerebral blood flow response to apneas." @default.
• W2000309674 created "2016-06-24" @default.
• W2000309674 creator A5002950929 @default.
• W2000309674 creator A5017935211 @default.
• W2000309674 creator A5040327052 @default.
• W2000309674 creator A5052740082 @default.
• W2000309674 creator A5056545763 @default.
• W2000309674 creator A5063709652 @default.
• W2000309674 creator A5074921493 @default.
• W2000309674 creator A5079501364 @default.
• W2000309674 creator A5083756625 @default.
• W2000309674 date "2014-08-01" @default.
• W2000309674 modified "2023-10-10" @default.
• W2000309674 title "Cerebral Oxygenation in Patients With OSA" @default.
• W2000309674 cites W1965141648 @default.
• W2000309674 cites W196857102 @default.
• W2000309674 cites W1971144058 @default.
• W2000309674 cites W2004914263 @default.
• W2000309674 cites W2015667309 @default.
• W2000309674 cites W2026191693 @default.
• W2000309674 cites W2028184696 @default.
• W2000309674 cites W2031872360 @default.
• W2000309674 cites W2033249270 @default.
• W2000309674 cites W2034623335 @default.
• W2000309674 cites W2054501537 @default.
• W2000309674 cites W2068113933 @default.
• W2000309674 cites W2068419813 @default.
• W2000309674 cites W2082244627 @default.
• W2000309674 cites W2084305955 @default.
• W2000309674 cites W2087538899 @default.
• W2000309674 cites W2089255087 @default.
• W2000309674 cites W2089511567 @default.
• W2000309674 cites W2096732105 @default.
• W2000309674 cites W2099072339 @default.
• W2000309674 cites W2103338199 @default.
• W2000309674 cites W2110661779 @default.
• W2000309674 cites W2112299151 @default.
• W2000309674 cites W2118123148 @default.
• W2000309674 cites W2137163826 @default.
• W2000309674 cites W2154909140 @default.
• W2000309674 cites W2162151689 @default.
• W2000309674 cites W35951801 @default.
• W2000309674 cites W4233235818 @default.
• W2000309674 doi "https://doi.org/10.1378/chest.13-2967" @default.
• W2000309674 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24811331" @default.
• W2000309674 hasPublicationYear "2014" @default.
• W2000309674 type Work @default.
• W2000309674 sameAs 2000309674 @default.
• W2000309674 citedByCount "37" @default.
• W2000309674 countsByYear W20003096742015 @default.
• W2000309674 countsByYear W20003096742016 @default.
• W2000309674 countsByYear W20003096742017 @default.
• W2000309674 countsByYear W20003096742018 @default.
• W2000309674 countsByYear W20003096742019 @default.
• W2000309674 countsByYear W20003096742020 @default.
• W2000309674 countsByYear W20003096742021 @default.
• W2000309674 countsByYear W20003096742022 @default.
• W2000309674 countsByYear W20003096742023 @default.
• W2000309674 crossrefType "journal-article" @default.
• W2000309674 hasAuthorship W2000309674A5002950929 @default.
• W2000309674 hasAuthorship W2000309674A5017935211 @default.
• W2000309674 hasAuthorship W2000309674A5040327052 @default.
• W2000309674 hasAuthorship W2000309674A5052740082 @default.
• W2000309674 hasAuthorship W2000309674A5056545763 @default.
• W2000309674 hasAuthorship W2000309674A5063709652 @default.
• W2000309674 hasAuthorship W2000309674A5074921493 @default.
• W2000309674 hasAuthorship W2000309674A5079501364 @default.
• W2000309674 hasAuthorship W2000309674A5083756625 @default.
• W2000309674 hasConcept C105702510 @default.
• W2000309674 hasConcept C126322002 @default.
• W2000309674 hasConcept C142724271 @default.
• W2000309674 hasConcept C164705383 @default.
• W2000309674 hasConcept C204787440 @default.
• W2000309674 hasConcept C27081682 @default.
• W2000309674 hasConcept C2777405951 @default.
• W2000309674 hasConcept C2777711342 @default.
• W2000309674 hasConcept C2778205975 @default.
• W2000309674 hasConcept C2780124106 @default.
• W2000309674 hasConcept C2781326671 @default.
• W2000309674 hasConcept C42219234 @default.
• W2000309674 hasConcept C70289976 @default.
• W2000309674 hasConcept C71924100 @default.
• W2000309674 hasConcept C8240015 @default.
• W2000309674 hasConcept C87813604 @default.
• W2000309674 hasConceptScore W2000309674C105702510 @default.
• W2000309674 hasConceptScore W2000309674C126322002 @default.
• W2000309674 hasConceptScore W2000309674C142724271 @default.
• W2000309674 hasConceptScore W2000309674C164705383 @default.
• W2000309674 hasConceptScore W2000309674C204787440 @default.
• W2000309674 hasConceptScore W2000309674C27081682 @default.
• W2000309674 hasConceptScore W2000309674C2777405951 @default.
• W2000309674 hasConceptScore W2000309674C2777711342 @default.
• W2000309674 hasConceptScore W2000309674C2778205975 @default.
• W2000309674 hasConceptScore W2000309674C2780124106 @default.
• W2000309674 hasConceptScore W2000309674C2781326671 @default.
• W2000309674 hasConceptScore W2000309674C42219234 @default.
• W2000309674 hasConceptScore W2000309674C70289976 @default.
• W2000309674 hasConceptScore W2000309674C71924100 @default.

• next